Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Aura Biosciences Inc ( (AURA) ).
On June 17, 2025, Aura Biosciences, Inc. held its 2025 Annual Meeting of Stockholders, where key proposals were voted upon. The stockholders elected Elisabet de los Pinos, Ph.D., and Giovanni Mariggi, Ph.D., as Class I directors to the Board of Directors, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and financial oversight positively.
The most recent analyst rating on (AURA) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Aura Biosciences Inc stock, see the AURA Stock Forecast page.
Spark’s Take on AURA Stock
According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.
Aura Biosciences’ overall stock score reflects its early-stage biotech profile, characterized by no revenue, increasing losses, and negative cash flows. While the company maintains a solid balance sheet, its stock faces bearish technical indicators and speculative valuation. The recent board appointment is a positive development, but the company’s financial health and market trends remain the primary concerns.
To see Spark’s full report on AURA stock, click here.
More about Aura Biosciences Inc
Aura Biosciences, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for the treatment of cancer. The company is primarily engaged in the research and development of targeted therapies that address unmet medical needs in oncology.
Average Trading Volume: 297,357
Technical Sentiment Signal: Sell
Current Market Cap: $396.8M
For an in-depth examination of AURA stock, go to TipRanks’ Overview page.